UroGen Pharma (URGN) highlighted results from a long-term follow-up study with Jelmyto for pyelocalyceal solution, which is FDA approved for ...

Royalty Pharma (RPRX) expects 2025 Portfolio Receipts to be between $2,900 million and $3,050 million, representing expected growth of 4% to ...

The company projects portfolio receipts for 2025 to range between $2.9 billion and $3.05 billion, representing 4-9% growth. Guidance incorporates scenarios for key products like Vertex's new triple ...

ICON plc, a clinical research organization, expanded its portfolio of artificial intelligence (AI) tools that aim to deliver efficiencies across the clinical trial process, including study startup, ...

The transaction, expected to close in the first half of this year, will cost Novartis $925 million upfront with potential ...

ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced the expansion of its portfolio of artificial intelligence (AI ...

and portfolio pricing. Given the evolving pressures in the pharmaceutical industry, manufacturers must take a proactive approach to navigating the challenges ahead. First and foremost, they should ...

West Pharmaceutical Services, Inc. WST is well poised for growth, backed by the robust Proprietary Products segment and sustained strength in research and development (R&D). However, foreign ...

Headquartered in Dublin, Ireland, ICON Public Limited Company ... Group and sluggish biotechnology and pharmaceutical R&D spending negatively impacting portfolio holding Thermo Fisher Scientific.

Matt Barnes, EVP, President of Nxera Pharma UK and Head of R&D, commented: “It is extremely encouraging to see the progress being made by Neurocrine across this exciting portfolio of muscarinic ...

ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced ...